University of Virginia Cancer Center: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Moved section down due to prioritize research. Corrected locations and cited.
→‎Research: section updated with specialties, discoveries, and partner networks
Line 39: Line 39:
The University of Virginia Cancer Center was founded in 1984 and has been NCI-designated since 1987.<ref>{{cite web|url=https://www.cancer.gov/research/nci-role/cancer-centers/find/uvacc |title=University of Virginia Cancer Center - National Cancer Institute |publisher=Cancer.gov |date=2012-07-26 |accessdate=2016-12-12}}</ref> This status is reviewed every five years.<ref name="hacva">{{cite web|title=Virginia State House Appropriations Committee on Higher Education|url=http://hac.state.va.us/subcommittee/2014_subcommittee/higher_education/files/01-20-14/Agenda%20Item%20III%20(3)%20Comprehensive%20designation%20goal%20and%20funding%20handout%201-17-14%20FINAL.pdf}}</ref> Its comprehensive designation became effective February 1, 2022.<ref>{{Cite web |date=2021-11-19 |title=Tom Loughran tells us how he got UVA over the hump to comprehensive designation |url=https://cancerletter.com/conversation-with-the-cancer-letter/20211119_1/ |access-date=2023-01-18 |website=The Cancer Letter |language=en-US}}</ref>
The University of Virginia Cancer Center was founded in 1984 and has been NCI-designated since 1987.<ref>{{cite web|url=https://www.cancer.gov/research/nci-role/cancer-centers/find/uvacc |title=University of Virginia Cancer Center - National Cancer Institute |publisher=Cancer.gov |date=2012-07-26 |accessdate=2016-12-12}}</ref> This status is reviewed every five years.<ref name="hacva">{{cite web|title=Virginia State House Appropriations Committee on Higher Education|url=http://hac.state.va.us/subcommittee/2014_subcommittee/higher_education/files/01-20-14/Agenda%20Item%20III%20(3)%20Comprehensive%20designation%20goal%20and%20funding%20handout%201-17-14%20FINAL.pdf}}</ref> Its comprehensive designation became effective February 1, 2022.<ref>{{Cite web |date=2021-11-19 |title=Tom Loughran tells us how he got UVA over the hump to comprehensive designation |url=https://cancerletter.com/conversation-with-the-cancer-letter/20211119_1/ |access-date=2023-01-18 |website=The Cancer Letter |language=en-US}}</ref>


The center's director, [[Thomas P. Loughran Jr.]], discovered and is considered a leading expert in large granular lymphocytic (LGL) leukemia. He succeeded [[Michael J. Weber]], who stepped down in 2013 after twelve years of service.<ref>{{Cite news|url=http://newsroom.uvahealth.com/2013/05/20/thomas-p-loughran-jr-md-appointed-director-of-uva-cancer-center/|title=Thomas P. Loughran Jr., MD, appointed director of UVA Cancer Center|date=2013-05-20|work=UVA Health Newsroom|access-date=2017-12-13|language=en-US}}</ref>
The center's director, [[Thomas P. Loughran Jr.]], discovered and is considered a leading expert in [[Large granular lymphocytic leukemia|large granular lymphocytic]] (LGL) leukemia. He succeeded [[Michael J. Weber]], who stepped down in 2013 after twelve years of service.<ref>{{Cite news|url=http://newsroom.uvahealth.com/2013/05/20/thomas-p-loughran-jr-md-appointed-director-of-uva-cancer-center/|title=Thomas P. Loughran Jr., MD, appointed director of UVA Cancer Center|date=2013-05-20|work=UVA Health Newsroom|access-date=2017-12-13|language=en-US}}</ref>


UVA Cancer Center is funded as a partner in the federal [[21st Century Cures Act|Cancer Moonshot]].<ref>{{Cite web |date=2017-01-25 |title=Giant Leap Against Cancer: UVA a Lead Institution in ‘Cancer Moonshot’ |url=https://news.virginia.edu/content/giant-leap-against-cancer-uva-lead-institution-cancer-moonshot |access-date=2023-01-18 |website=UVA Today |language=en}}</ref> The initiative is led by the Biden Administration and in 2022 set new goals of reducing the cancer death rate by half within 25 years while improving the lives of people with cancer and cancer survivors. <ref>{{Cite web |title=Cancer Moonshot |url=https://www.whitehouse.gov/cancermoonshot/ |access-date=2023-01-18 |website=The White House |language=en-US}}</ref>
UVA Cancer Center is funded as a partner in the federal [[21st Century Cures Act|Cancer Moonshot]].<ref>{{Cite web |date=2017-01-25 |title=Giant Leap Against Cancer: UVA a Lead Institution in ‘Cancer Moonshot’ |url=https://news.virginia.edu/content/giant-leap-against-cancer-uva-lead-institution-cancer-moonshot |access-date=2023-01-18 |website=UVA Today |language=en}}</ref> The initiative is led by the Biden Administration and in 2022 set new goals of reducing the cancer death rate by half within 25 years while improving the lives of people with cancer and cancer survivors. <ref>{{Cite web |title=Cancer Moonshot |url=https://www.whitehouse.gov/cancermoonshot/ |access-date=2023-01-18 |website=The White House |language=en-US}}</ref>
Line 48: Line 48:


== Research ==
== Research ==
The UVA Cancer Center’s member researchers represent UVA’s schools of Medicine, Nursing, Engineering and Applied Science, Education, Data Science, and the College of Arts and Sciences. Its primary research is divided into four collaborative, transdisciplinary programs:<ref>{{Cite web |title=Research Programs |url=https://med.virginia.edu/cancer-research/research-initiatives/research-programs/ |access-date=2023-01-18 |website=UVA Comprehensive Cancer Center |language=en-US}}</ref>
The UVA Cancer Center’s member researchers represent UVA’s schools of Medicine, [[University of Virginia School of Nursing|Nursing]], Engineering and Applied Science, Education, Data Science, and the [[University of Virginia College of Arts and Sciences|College of Arts and Sciences]]. Its primary research is divided into four collaborative, transdisciplinary programs:<ref>{{Cite web |title=Research Programs |url=https://med.virginia.edu/cancer-research/research-initiatives/research-programs/ |access-date=2023-01-18 |website=UVA Comprehensive Cancer Center |language=en-US}}</ref>
* Cancer Biology
* Cancer Biology
* Molecular Genetics and Epigenetics
* Molecular Genetics and Epigenetics
Line 54: Line 54:
* Cancer Prevention and Population Health
* Cancer Prevention and Population Health


The UVA Cancer Center is a leader in research and treatment of [[Tumors of the hematopoietic and lymphoid tissues|rare blood cancers]] and in research and development of [[High-intensity focused ultrasound|focused ultrasound]] in cancer treatment. The center is affiliated with UVA’s Translational Orphan Blood Cancer Research Initiative, which pursues new therapies for rare cancers that lack the funding afforded more common cancers, and with the School of Medicine’s Focused Ultrasound Cancer Immunotherapy Center.<ref>{{Cite web |date=2022-08-04 |title=UVA Cancer Center Receives $5.75 Million to Battle Rare Blood Cancers |url=https://newsroom.uvahealth.com/2022/08/04/uva-cancer-center-receives-5-75-million-gift-rare-blood-cancers/ |access-date=2023-01-20 |website=UVA Health Newsroom |language=en-US}}</ref><ref>{{Cite web |title=About |url=https://med.virginia.edu/uva-focused-ultrasound-cancer-immunotherapy-center/about/ |access-date=2023-01-20 |website=Focused Ultrasound Cancer Immunotherapy Center |language=en-US}}</ref>
UVA Cancer Center is a member of the Oncology Research Information Exchange Network (ORIEN), a group of 16 institutions nationwide dedicated to cancer research, with the sharing data to further the development of personalized medicine and expedite access to clinical trials.<ref>{{Cite web|url=http://oriencancer.org/#about|title=ORIEN {{!}} Oncology Research Information Exchange Network|website=oriencancer.org|language=en-US|access-date=2017-12-13}}</ref> Patients can become "Partners in Discovery" by consenting to donate leftover tumor tissue from surgery and information about their health and cancer treatment. This is added to the database which is accessible to scientists at participating institutions.<ref>{{Cite web|url=https://cancer.uvahealth.com/research/partners-in-discovery|title=Partners in Discovery — UVA Cancer Center|last=D|first=Benner, Julia|website=cancer.uvahealth.com|language=en|access-date=2017-12-13}}</ref>

UVA Cancer Center’s research findings include:

* Discovery of the gene responsible for [[glioblastoma]], the deadliest form of brain cancer. UVA researchers also found that the same gene factors in two forms of the childhood cancer [[rhabdomyosarcoma]].<ref>{{Cite web |last=Jackson |first=Christina |date=2020-07-15 |title=Scientists Pinpoint Onocogene that Drives Deadly Brain Cancer |url=https://www.genengnews.com/news/scientists-pinpoint-onocogene-that-drives-deadly-brain-cancer/ |access-date=2023-01-20 |website=GEN - Genetic Engineering and Biotechnology News |language=en-US}}</ref>
* Identification of a gene contributing to [[Small-cell carcinoma|small-cell lung cancer]], that when manipulated halted the disease’s spread in mice<ref>{{Cite web |date=2022-02-24 |title=Surprise Discovery Suggests New Treatment for Small-Cell Lung Cancer |url=https://newsroom.uvahealth.com/2022/02/24/surprise-discovery-suggests-new-treatment-for-small-cell-lung-cancer/ |access-date=2023-01-20 |website=UVA Health Newsroom |language=en-US}}</ref>
* Discovery of link between the gut biome and the spread of [[breast cancer]]<ref>{{Cite web |last=PM |first=The ASCO Post Staff Posted: 9/28/2022 1:05:00 PM Last Updated: 9/28/2022 1:17:43 |title=Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals - The ASCO Post |url=https://ascopost.com/news/september-2022/unhealthy-gut-may-set-the-stage-for-breast-cancer-to-spread-preclinical-research-reveals/ |access-date=2023-01-20 |website=ascopost.com |language=en}}</ref>
* Discovery of an inhibitor protein that is inactive in patients with hard-to-treat “[[Triple-negative breast cancer|triple negative]]” breast cancer<ref>{{Cite web |date=2017-11-20 |title=UVA Researchers Discover a New Target for ‘Triple-Negative’ Breast Cancer |url=https://news.virginia.edu/content/uva-researchers-discover-new-target-triple-negative-breast-cancer |access-date=2023-01-20 |website=UVA Today |language=en}}</ref>
* Analysis determining that Black and Asian [[lung cancer]] patients wait averages of 5 and 11 days longer than white patients for initiation of [[radiation therapy]], respectively<ref>{{Cite web |title=Minorities face longer wait times for vital lung cancer treatment, study finds |url=https://www.sciencedaily.com/releases/2022/10/221025090509.htm |access-date=2023-01-20 |website=ScienceDaily |language=en}}</ref>
* Discovery of a form of [[RNA]] prevalent in [[Prostate cancer|prostate cancers]] that could serve as a target for treatments<ref>{{Cite journal |last=Ta |first=Huy Q. |last2=Whitworth |first2=Hilary |last3=Yin |first3=Yi |last4=Conaway |first4=Mark |last5=Frierson |first5=Henry F. |last6=Campbell |first6=Moray J. |last7=Raj |first7=Ganesh V. |last8=Gioeli |first8=Daniel |date=2019-06-28 |title=Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |url=https://pubmed.ncbi.nlm.nih.gov/31253147/ |journal=Molecular Cancer |volume=18 |issue=1 |pages=113 |doi=10.1186/s12943-019-1039-6 |issn=1476-4598 |pmc=6598369 |pmid=31253147}}</ref>

UVA Cancer Center is a member of the Oncology Research Information Exchange Network (ORIEN), a group of 16 institutions, as well as the [[Cooperative Human Tissue Network]], the Lung Cancer Biospecimen Research Network, and the Applied Proteogenomics and Learning (APOLLO) program.

Patients who receive cancer treatment at UVA can participate in its Partners in Discovery program by consenting to donate tumor tissue from surgeries and information about their health and treatment. Analyses of these specimens and other data is anonymously entered into the nationwide databases to support research, to further the development of personalized medicine, and to expedite access to clinical trials.<ref>{{Cite web |title=Partners in Discovery |url=https://med.virginia.edu/cancer-research/research-resources/partners-in-discovery/ |access-date=2023-01-20 |website=UVA Comprehensive Cancer Center |language=en-US}}</ref>


== Locations ==
== Locations ==

Revision as of 20:52, 20 January 2023

Established1984
DirectorThomas P. Loughran Jr.[1]
Location
Charlottesville
,
Virginia
Websitehttps://med.virginia.edu/cancer-research/

University of Virginia Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center affiliated with the University of Virginia School of Medicine and the UVA Health System.[2][3][4]

Focused on research and education, UVA Cancer Center has more than 175 member faculty researchers supported by approximately $75 million in annual funding. The center also conducts regional outreach to improve awareness of cancer risks and access to screening and treatment.[5]

UVA Cancer Center is one of 53 comprehensive designated by the NCI, and the only one in Virginia.[6]

History

The University of Virginia Cancer Center was founded in 1984 and has been NCI-designated since 1987.[7] This status is reviewed every five years.[8] Its comprehensive designation became effective February 1, 2022.[9]

The center's director, Thomas P. Loughran Jr., discovered and is considered a leading expert in large granular lymphocytic (LGL) leukemia. He succeeded Michael J. Weber, who stepped down in 2013 after twelve years of service.[10]

UVA Cancer Center is funded as a partner in the federal Cancer Moonshot.[11] The initiative is led by the Biden Administration and in 2022 set new goals of reducing the cancer death rate by half within 25 years while improving the lives of people with cancer and cancer survivors. [12]

UVA Cancer Center is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT).[13] It is a leader in treatment of myelodysplastic syndrome and an MDS Foundation Center of Excellence.[14]

In 2016, a $112 million partnership was announced between the UVA Cancer Center and the Inova Schar Cancer Institute to develop a regional institute in Northern Virginia.[15][16]

Research

The UVA Cancer Center’s member researchers represent UVA’s schools of Medicine, Nursing, Engineering and Applied Science, Education, Data Science, and the College of Arts and Sciences. Its primary research is divided into four collaborative, transdisciplinary programs:[17]

  • Cancer Biology
  • Molecular Genetics and Epigenetics
  • Cancer Therapeutics
  • Cancer Prevention and Population Health

The UVA Cancer Center is a leader in research and treatment of rare blood cancers and in research and development of focused ultrasound in cancer treatment. The center is affiliated with UVA’s Translational Orphan Blood Cancer Research Initiative, which pursues new therapies for rare cancers that lack the funding afforded more common cancers, and with the School of Medicine’s Focused Ultrasound Cancer Immunotherapy Center.[18][19]

UVA Cancer Center’s research findings include:

  • Discovery of the gene responsible for glioblastoma, the deadliest form of brain cancer. UVA researchers also found that the same gene factors in two forms of the childhood cancer rhabdomyosarcoma.[20]
  • Identification of a gene contributing to small-cell lung cancer, that when manipulated halted the disease’s spread in mice[21]
  • Discovery of link between the gut biome and the spread of breast cancer[22]
  • Discovery of an inhibitor protein that is inactive in patients with hard-to-treat “triple negative” breast cancer[23]
  • Analysis determining that Black and Asian lung cancer patients wait averages of 5 and 11 days longer than white patients for initiation of radiation therapy, respectively[24]
  • Discovery of a form of RNA prevalent in prostate cancers that could serve as a target for treatments[25]

UVA Cancer Center is a member of the Oncology Research Information Exchange Network (ORIEN), a group of 16 institutions, as well as the Cooperative Human Tissue Network, the Lung Cancer Biospecimen Research Network, and the Applied Proteogenomics and Learning (APOLLO) program.

Patients who receive cancer treatment at UVA can participate in its Partners in Discovery program by consenting to donate tumor tissue from surgeries and information about their health and treatment. Analyses of these specimens and other data is anonymously entered into the nationwide databases to support research, to further the development of personalized medicine, and to expedite access to clinical trials.[26]

Locations

The UVA Cancer Center is based at UVA Health. Outpatient treatment is provided at the Emily Couric Clinical Cancer Center (ECCCC) in Charlottesville and at satellite clinics in Albemarle and Augusta counties and in Culpeper, Virginia.[27] The ECCCC is a 150,000 square-foot facility built at a cost of $74 million.[28] It was dedicated in 2011 and named for state senator Emily Couric, who died of pancreatic cancer in 2001.[29]

Notable people

References

  1. ^ "UVA Cancer Center appoints new director Company News | Virginia Business". www.virginiabusiness.com. 21 May 2013.
  2. ^ "UVA Earns Comprehensive Cancer Center Designation". UVA Today. 2021-08-27. Retrieved 2023-01-18.
  3. ^ "UVA Comprehensive Cancer Center". UVA Comprehensive Cancer Center. Retrieved 2023-01-18.
  4. ^ "Cancer Center: Innovative Cancer Care | UVA Health". uvahealth.com. Retrieved 2023-01-18.
  5. ^ "About Us". UVA Comprehensive Cancer Center. Retrieved 2023-01-18.
  6. ^ "Find an NCI-Designated Cancer Center - NCI". www.cancer.gov. 2012-08-13. Retrieved 2023-01-18.
  7. ^ "University of Virginia Cancer Center - National Cancer Institute". Cancer.gov. 2012-07-26. Retrieved 2016-12-12.
  8. ^ "Virginia State House Appropriations Committee on Higher Education" (PDF).
  9. ^ "Tom Loughran tells us how he got UVA over the hump to comprehensive designation". The Cancer Letter. 2021-11-19. Retrieved 2023-01-18.
  10. ^ "Thomas P. Loughran Jr., MD, appointed director of UVA Cancer Center". UVA Health Newsroom. 2013-05-20. Retrieved 2017-12-13.
  11. ^ "Giant Leap Against Cancer: UVA a Lead Institution in 'Cancer Moonshot'". UVA Today. 2017-01-25. Retrieved 2023-01-18.
  12. ^ "Cancer Moonshot". The White House. Retrieved 2023-01-18.
  13. ^ "FACT Accredited Institutions". Retrieved 2023-01-18.
  14. ^ "MDS Centers of Excellence | MDS Foundation". Retrieved 2023-01-18.
  15. ^ "Inova and UVA to Develop a Comprehensive Cancer Center – The Cancer Letter Publications". cancerletter.com. 4 November 2016. Retrieved 2017-12-13.
  16. ^ Reed, Tina (November 2, 2016). "Here are the details of the new $112M partnership between Inova and UVa". www.bizjournals.com. Retrieved 2017-12-13.
  17. ^ "Research Programs". UVA Comprehensive Cancer Center. Retrieved 2023-01-18.
  18. ^ "UVA Cancer Center Receives $5.75 Million to Battle Rare Blood Cancers". UVA Health Newsroom. 2022-08-04. Retrieved 2023-01-20.
  19. ^ "About". Focused Ultrasound Cancer Immunotherapy Center. Retrieved 2023-01-20.
  20. ^ Jackson, Christina (2020-07-15). "Scientists Pinpoint Onocogene that Drives Deadly Brain Cancer". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-01-20.
  21. ^ "Surprise Discovery Suggests New Treatment for Small-Cell Lung Cancer". UVA Health Newsroom. 2022-02-24. Retrieved 2023-01-20.
  22. ^ PM, The ASCO Post Staff Posted: 9/28/2022 1:05:00 PM Last Updated: 9/28/2022 1:17:43. "Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals - The ASCO Post". ascopost.com. Retrieved 2023-01-20.{{cite web}}: CS1 maint: numeric names: authors list (link)
  23. ^ "UVA Researchers Discover a New Target for 'Triple-Negative' Breast Cancer". UVA Today. 2017-11-20. Retrieved 2023-01-20.
  24. ^ "Minorities face longer wait times for vital lung cancer treatment, study finds". ScienceDaily. Retrieved 2023-01-20.
  25. ^ Ta, Huy Q.; Whitworth, Hilary; Yin, Yi; Conaway, Mark; Frierson, Henry F.; Campbell, Moray J.; Raj, Ganesh V.; Gioeli, Daniel (2019-06-28). "Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth". Molecular Cancer. 18 (1): 113. doi:10.1186/s12943-019-1039-6. ISSN 1476-4598. PMC 6598369. PMID 31253147.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  26. ^ "Partners in Discovery". UVA Comprehensive Cancer Center. Retrieved 2023-01-20.
  27. ^ "UVA Community Oncology Network" Retrieved 2023-01-20.
  28. ^ "UVA Health System Emily Couric Clinical Cancer Center - Gilbane". Gilbaneco.com. Retrieved 2016-12-12.
  29. ^ "Katie Couric Helps Dedicate Emily Couric Clinical Cancer Center". UVA Today. 2011-02-28. Retrieved 2023-01-20.
  30. ^ "Hershey doctor's pioneering work with rare leukemia offers hope to patients worldwide". PennLive.com. 2012-07-16. Retrieved 2016-12-12.

Retrieved from "https://en.wikipedia.org/w/index.php?title=University_of_Virginia_Cancer_Center&oldid=1134815523"